Learn About Chronic Graft Versus Host Disease (cGvHD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Gerard Socie practices in Paris, France. Mr. Socie is rated as an Elite expert by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Aplastic Anemia, Bone Marrow Transplant, and Bone Graft.
Dana-Farber Cancer Institute, Inc.
Corey Cutler is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cutler is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
Joseph Pidala is an Oncologist in Tampa, Florida. Dr. Pidala is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Pidala is currently accepting new patients.
Summary: The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation an...
Summary: This is an open-label phase I study of fostamatinib in combination with ruxolitinib for the treatment of chronic GvHD with a suboptimal response to corticosteroids. The primary objective is to identify a minimum safe and biologically effective dose of fostamatinib when combined with standard of care ruxolitinib for the treatment of steroid refractory and steroid dependent cGVHD. The secondary obje...